Cargando…

Current perspectives on bone metastases in castrate-resistant prostate cancer

Prostate cancer is the most frequent noncutaneous cancer occurring in men. On average, men with localized prostate cancer have a high 10-year survival rate, and many can be cured. However, men with metastatic castrate-resistant prostate cancer have incurable disease with poor survival despite intens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Logothetis, Christopher, Morris, Michael J., Den, Robert, Coleman, Robert E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5801387/ https://www.ncbi.nlm.nih.gov/pubmed/29380085 http://dx.doi.org/10.1007/s10555-017-9719-4

Ejemplares similares

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Pain in castration-resistant prostate cancer with bone metastases: a qualitative study
por: Gater, Adam, et al.
Publicado: (2011)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Transdermal estradiol in castrate and chemotherapy resistant prostate cancer
por: Stein, Mark, et al.
Publicado: (2012)

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases
por: Lobo-Martins, Soraia, et al.
Publicado: (2020)

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
por: Lorente, David, et al.
Publicado: (2016)

Impact of treatment on progression to castration‐resistance, metastases, and death in men with localized high‐grade prostate cancer
por: Miller, Eric T., et al.
Publicado: (2016)

Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone
por: Pan, Tianhong, et al.
Publicado: (2021)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
por: Koie, Takuya, et al.
Publicado: (2020)

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases
por: Kapoor, Anil, et al.
Publicado: (2019)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
por: Meyer, Andrew, et al.
Publicado: (2012)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Current Treatment Strategies for Castration-Resistant Prostate Cancer
por: Kim, Se Joong, et al.
Publicado: (2011)

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
por: Hörnberg, Emma, et al.
Publicado: (2011)

Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer
por: Cursano, Maria Concetta, et al.
Publicado: (2023)

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: Luo, Jia, et al.
Publicado: (2016)

Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: El-Amm, Joelle, et al.
Publicado: (2017)

Exercise Preserves Physical Function in Prostate Cancer Patients with Bone Metastases
por: GALVÃO, DANIEL A., et al.
Publicado: (2018)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
por: Le, Thi Khanh, et al.
Publicado: (2023)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Castration for Prostatic Hypertrophy
Publicado: (1899)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
por: Heidenreich, Axel, et al.
Publicado: (2019)

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer
por: Tucker, Matthew D., et al.
Publicado: (2019)

Case Series: “Silent” Spinal Epidural Metastases in Metastatic Castrate-Resistant Prostate Cancer
por: Sabanathan, Dhanusha, et al.
Publicado: (2023)

Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
por: Mofid, Bahram, et al.
Publicado: (2015)

Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer
por: Moreira, Daniel M., et al.
Publicado: (2015)

Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice
por: Patel, Priyanka H., et al.
Publicado: (2022)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o8uestpqo4qjsfn3k8e7co1hnl